Ballew Advisors’s Genetic Technologies Ltd. GENE Stock Holding History

Ballew Advisors’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-95	Closed	-$2K	–	464
2018 Q3	$2K	Buy	+95	New	+$2.16K	﹤0.01%	416

Other funds holding GENE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Ballew Advisors's GENE Position: Q4 2018 in Review

Ballew Advisors sold out of Genetic Technologies Ltd. (GENE) in Q4 2018, closing a stake of 95 shares — an estimated $2K sold.

Ballew Advisors first reported a position in GENE in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 11 funds tracked by Wall St. Rank hold GENE as of Q4 2018.

Ballew Advisors reported no remaining Genetic Technologies Ltd. position as of Q4 2018 after selling out during the quarter.
Ballew Advisors sold 95 Genetic Technologies Ltd. shares in Q4 2018, an estimated $2K.
Ballew Advisors first reported a position in Genetic Technologies Ltd. in Q3 2018 and held it in 1 quarter.
Ballew Advisors's Genetic Technologies Ltd. position peaked at $2K in Q3 2018.
11 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.